Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Abbott Laboratories (NYSE: ABT) closed at $133.22 down -0.10% from its previous closing price of $133.36. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 4.61 million shares were traded. ABT stock price reached its highest trading level at $133.77 during the session, while it also had its lowest trading level at $131.47.
Ratios:
For a deeper understanding of Abbott Laboratories’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 33.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.78. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on June 16, 2025, initiated with a Market Perform rating and assigned the stock a target price of $143.
On October 08, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $130.
On September 19, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $131.Piper Sandler initiated its Overweight rating on September 19, 2024, with a $131 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 30 ’25 when Blount Sally E. sold 2,600 shares for $129.66 per share. The transaction valued at 337,116 led to the insider holds 34,058 shares of the business.
SALLY E BLOUNT bought 2,600 shares of ABT for $337,116 on Apr 30 ’25. On Mar 06 ’25, another insider, Earnhardt Lisa D, who serves as the EVP AND GROUP PRESIDENT of the company, sold 91,167 shares for $133.82 each. As a result, the insider received 12,199,968 and left with 71,928 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABT now has a Market Capitalization of 231781482496 and an Enterprise Value of 243334152192. As of this moment, Abbott’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.28, and their Forward P/E ratio for the next fiscal year is 23.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.67. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.47 while its Price-to-Book (P/B) ratio in mrq is 4.75. Its current Enterprise Value per Revenue stands at 5.747 whereas that against EBITDA is 22.079.
Stock Price History:
The Beta on a monthly basis for ABT is 0.71, which has changed by 0.27874827 over the last 52 weeks, in comparison to a change of 0.12153554 over the same period for the S&P500. Over the past 52 weeks, ABT has reached a high of $141.23, while it has fallen to a 52-week low of $99.71. The 50-Day Moving Average of the stock is -0.12%, while the 200-Day Moving Average is calculated to be 6.92%.
Shares Statistics:
For the past three months, ABT has traded an average of 6.56M shares per day and 6131880 over the past ten days. A total of 1.74B shares are outstanding, with a floating share count of 1.73B. Insiders hold about 0.67% of the company’s shares, while institutions hold 79.84% stake in the company. Shares short for ABT as of 1749772800 were 20799869 with a Short Ratio of 3.17, compared to 1747267200 on 22256461. Therefore, it implies a Short% of Shares Outstanding of 20799869 and a Short% of Float of 1.2.
Dividends & Splits
According to the company, the forward annual dividend rate for ABT is 2.28, from 2.28 in the trailing year. Against a Trailing Annual Dividend Yield of 0.017096581The stock’s 5-year Average Dividend Yield is 1.67. The current Payout Ratio is 29.33% for ABT, which recently paid a dividend on 2025-04-15 with an ex-dividend date of 1752537600. Stock splits for the company last occurred on 2013-01-02 when the company split stock in a 10000:4798 ratio.
Earnings Estimates
The market rating for Abbott Laboratories (ABT) is a result of the insights provided by 22.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $1.33, with high estimates of $1.39 and low estimates of $1.21.
Analysts are recommending an EPS of between $5.2 and $5.08 for the fiscal current year, implying an average EPS of $5.16. EPS for the following year is $5.68, with 26.0 analysts recommending between $5.82 and $5.56.
Revenue Estimates
A total of 22 analysts believe the company’s revenue will be $11.02B this quarter.It ranges from a high estimate of $11.27B to a low estimate of $10.38B. As of the current estimate, Abbott Laboratories’s year-ago sales were $10.38BFor the next quarter, 22 analysts are estimating revenue of $11.35B. There is a high estimate of $11.5B for the next quarter, whereas the lowest estimate is $10.63B.
A total of 26 analysts have provided revenue estimates for ABT’s current fiscal year. The highest revenue estimate was $45.1B, while the lowest revenue estimate was $44.1B, resulting in an average revenue estimate of $44.63B. In the same quarter a year ago, actual revenue was $41.95BBased on 26 analysts’ estimates, the company’s revenue will be $48.03B in the next fiscal year. The high estimate is $49.07B and the low estimate is $47.05B.
